Arrowhead, Despite Ailing Stock, Reloads in RNAi Hepatitis B Fight
Summary
The data, released in October, prompted multiple law firms to file lawsuits on behalf of investors against Arrowhead, alleging that the company misled them about the experimental drug’s potency.A big stumbling block for developers of these drugs has been finding reliable ways to deliver the short RNA strands that they’re based upon to diseased cells before the delicate molecules break down.Arrowhead’s approach to this problem is to use polymer nanoparticles called dynamic polyconjugates to shepherd the RNAs through the body, shielding them from destructive enzymes until they reach the target cells.We’re really excited about that.” But that theory still needs to be proven in additional clinical trials, and the company must demonstrate the drug’s safety with a larger group of patients, Anzalone says.Arrowhead filed an investigational new drug application with the FDA this week, and it’s planning to seek approval for similar studies in Europe and Asia.